吉姆图祖马布臭加米辛的安全性评估:基于FDA不良事件报告系统的现实世界不良事件分析
Xuexue Liu1, Fang Wu2, Zhuoyan Li1
1Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Frontiers in medicine
|September 29, 2025
概括
这项研究分析了FDA不良事件报告系统 (FAERS) 的数据,以确定与gemtuzumab ozogamicin相关的不良药事件 (ADEs). 检测到新的高风险信号,如密码化组织性肺炎,强调需要加强药物监测.
科学领域:
- 药监和药物安全 药监和药物安全
- 现实世界的证据分析分析.
- 瘤学 药物安全 药物安全
背景情况:
- 吉姆图祖马布 (gemtuzumab ozogamicin) 是一种用于癌症治疗的药物.
- 了解其不良药物事件 (ADEs) 对患者安全至关重要.
- 现实世界的数据分析可以揭示安全信号.
研究的目的:
- 使用FDA不良事件报告系统 (FAERS) 数据,挖掘与gemtuzumab ozogamicin相关的不良药事件 (ADEs).
- 为临床实践中gemtuzumab ozogamicin的安全性评估提供证据.
- 为了确定与这种药物相关的新安全问题.
主要方法:
- 利用FAERS从2004年第一季度到2024年第三季度的数据,重点关注gemtuzumab ozogamicin作为主要的疑似药物.
- 采用多种统计方法,包括报告几率比率 (ROR),MHRA,BCPNN和MGPS用于信号检测.
- 分析了2,065份患者报告,以确定不良事件信号.
主要成果:
- 在2,065个患者报告中,确定了238个积极的不良药物事件信号.
- 发烧性中性质衰竭是最常见的ADE,而肝脏静脉封闭性疾病 (VOD) 显示最强的信号强度.
- 新发现的高风险信号包括密码性组织性肺炎 (COP) 和增加纤维素降解产物.
结论:
- 来自FAERS的现实世界证据确定了先前未被识别的gemtuzumab ozogamicin的ADEs.
- 临床医生和药剂师应优先管理高风险的ADEs,并加强合理的药物使用.
- 持续的药物监测和更新临床指南是必不可少的,特别是对于新发现的风险,如COP.
更多相关视频
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
3.2K
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
8.2K
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
FDA Approved Drugs: Changes to Approved Drugs
244
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
244
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
